Anavex Life Sciences announced new scientific evidence showing shared biological mechanisms between autism spectrum disorder (ASD) and Alzheimer's disease (AD), particularly involving impaired autophagy and synaptic dysfunction. These findings support the development of their oral drug blarcamesine, which targets SIGMAR1 to restore autophagy, a key cellular cleanup process disrupted in both conditions. Clinical trials have shown promising results in Alzheimer's, Rett syndrome, and Parkinson's disease dementia, and Anavex plans to advance blarcamesine into pivotal studies to further explore its potential across neurodevelopmental and neurodegenerative diseases. This research reframes brain disorders by highlighting common disease pathways, potentially leading to broader therapeutic applications.
Christopher Derrick, known for writing on Star Trek: Picard and The Equalizer, premieres his first film as sole writer-director, Moral Dirt, at the Academy Award® Qualifying LA Shorts International Film Festival on August 3, 2026. The 15-minute psych...
Arcutis Biotherapeutics has appointed Chris Peetz to its Board of Directors as of July 15, 2026. Peetz brings extensive experience leading biopharmaceutical companies through growth phases, product development, and strategic acquisitions. His additio...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
